17. INVENTORIES

	2019 R'm	2018 R'm
Ethical drugs and consumable products (including surgicals consumed as well as consumables related to the production of doses relating to the diagnostic services business)	**379**	360
"Drugs and consumables" represents the cost of inventories recorded as an expense in the statement of profit and loss.		
The cost of inventories written off as expired stock is recognised as an expense and is included in "drugs and consumables" in profit or loss. Inventories written off amounted to:	**9**	9

18. ASSET CLASSIFIED AS HELD FOR SALE (RELATING TO 2018 FINANCIAL YEAR)

Non-current asset held for sale		
Investment in Max	**–**	2 841
During the prior year the directors of the Group decided to dispose of its 49.7% equity shareholding in Max. The IFRS 5 criteria were met on 1 July 2018.		
Loss recognised in profit or loss and other comprehensive income	**–**	118
The results of Max as at the date of classified as held for sale (1 July 2018) are summarised as follows (not adjusted for the percentage ownership by the Group):		
Revenue	**n/a**	3 690
Depreciation and amortisation		(185)
Net finance costs		(183)
Tax expense		(6)
Total loss		(165)
The disposal of Max was concluded during the current year and the net proceeds were received on 21 June 2019 (refer note 26).		

19. STATED CAPITAL

Stated capital comprises:		
Share capital	**10 507**	10 507
Share premium	**3 373**	3 373
Treasury shares	**(365)**	(370)
	13 515	13 510
Reconciliation of number of shares		
Ordinary shares ('000)		
Authorised (share capital of R0.000001 each)	**4 149 980**	4 149 980
Total value = R4 149 (2018: R4 149)		
Issued and fully paid:		
Balance at 1 October	**1 467 349**	1 449 391
Shares issued as a result of scrip distributions	**–**	17 958
Balance at 30 September	**1 467 349**	1 467 349
Total value = R1 467 (2018: R1 467)		